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Sepsis and septic multiple organ failure are leading causes of
morbidity and death in critically ill patients. Alterations to the
patient’s immune system, with an excessive systemic
inflammatory response on one hand and paralysis of cell-
mediated immunity on the other, appear to be the key
elements in the pathogenesis of multiple organ failure and
susceptibility to infection. Thus far, immune-based
interventions have met with limited success, at least in phase
III trials. A better understanding of the immunopathogenesis
of multiple organ failure is needed if we are to develop new
therapeutic strategies.
During the past few years our knowledge in the field of
sepsis improved through the use of new animal models that
are closer to the human situation than were their
predecessors, and as a result of novel immune diagnostic
techniques. The paper by Angele and Faist [1] focuses on
the effects of blood loss and surgical injury on cell-mediated
responses, and it provides a comprehensive review on this
important issue. Those authors themselves significantly
contributed to our current ‘state of the art’ knowledge.
The studies summarized in that review indicate that injury,
trauma and blood loss result in a marked suppression in
cell-mediated immunity that is associated with an
increased susceptibility to wound infection and sepsis. In
particular, the alterations in monocyte/macrophage and
lymphocyte function are addressed. Monocytes from
patients after blood loss, trauma and major surgery
frequently exhibit depressed ex vivo secretion of tumour
necrosis factor (TNF), IL-12 and other cytokines in
response to lipopolysaccharide, and a downregulation in
HLA-DR expression and antigen-presenting capacity. In
addition, T cells, in particular type 1 cytokine-secreting T
cells, show functional abnormalities. In some clinical
situations an expansion of type 2 cytokine-secreting CD8+
T cells was observed. Moreover, B-cell deficiency was
detected.
In addition, the review notes important differences between
sexes in altered immune responsiveness following trauma,
injury and blood loss. It is well established that male critically
ill patients are more susceptible to infections and sepsis,
and have a higher mortality than do female patients. By
using murine models, it was demonstrated that sex
hormones and dehydroepiandrosterone play important roles
in sex-specific immune responsiveness following blood loss,
trauma and injury.
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Abstract
Multiple organ failure is the major problem in intensive care patients. The failure of the organ ‘immune
system’ is frequently overlooked, however. In this issue the article by Angele and Faist provides an
excellent review of the topic. Deactivation of monocyte and lymphocyte functions seems to play a key
role in post-traumatic immunodepression. To accompany that review we summarize our knowledge of
the mechanisms of deactivation. Stress response, lipopolysaccharide translocalization and tissue injury
contribute to ‘immunoparalysis’. Recently developed, well standardized assays now allow us to monitor
the immune system like other organ functions and opens new approaches for therapeutic interventions.
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On the basis of the well established observation of
immunodeficiency following trauma, blood loss and major
surgery, three questions arise. What are the mechanisms of
immune deactivation? Do we have standardized and
validated assays to detect the immunodeficiency? Finally, are
there any therapeutic options to reverse the immune
deactivation?
Mechanisms of immune deactivation
Activation of the stress response plays an important role in
downregulating systemic immune responsiveness following
trauma, injury and blood loss (Fig. 1). The regulatory role of
the hypothalamic–pituitary–adrenal axis, which can
stimulate corticosteroid release, is well established. Recent
data [2,3] show that the sympathetic nerve system and the
vagus are also involved in the regulation of immune
responsiveness. The three systems downregulate
monocyte/macrophage proinflammatory (e.g. TNF release)
and antigen-presenting functions both directly and
indirectly by induction of immunomodulatory cytokines (e.g.
IL-10). IL-10 also deactivates T cells, in particular type 1
cytokine-secreting T cells.
This interaction between immune and central nervous systems
is important for preventing excessive inflammatory reactions in
intensive care unit patients. If the response is transient, then
the beneficial effect dominates. However, extensive systemic
inflammation (e.g. following endotoxin translocalization or
severe infection) leads to a strong and long-lasting activation
of the immune deactivating stress axis, which increases
susceptibility to infection. In addition, high levels of
corticosteroids and catecholamines induce apoptosis of
lymphocytes, resulting in defects in the adaptive immune
system. Moreover, a strong inflammatory response of
monocyte/macrophages also directly deactivates these cells
via negative feedback mechanisms (endotoxin desensitization,
TNF-induced IL-10 and IL-1 receptor antagonist release, etc.).
Inflammation- and hypoxia-related tissue injury results in
release of apoptotic cells, which are taken up by
monocyte/macrophages via a receptor that deactivates their
inflammatory and antigen-presenting pathways.
In summary, the greater the inflammation and injury, the
greater the counter-regulation.
Measurement of immune responsiveness
During the past few decades several assays for
measurement of immune responsiveness have been reported.
A problem, however, is standardization of the assays. Many of
the assays developed thus far do not fulfill the criteria of a
modern diagnostic assay. As suggested in the review [1],
measures of monocyte/macrophage and T-cell function play
key roles in diagnosis. During the past few years some well
standardized assays for detecting monocytic cytokine
secretion (whole blood assay with semi-automatic cytokine
measurement), monocytic HLA-DR and CD86 expression
(quantitative flow cytometry, allowing counting of molecules
per cell), and T-cell cytokine profiling (differentiation of type
1/2 cytokine patterns by intracellular cytokine staining and
flow cytometric analysis) have been developed. Using
standard operation procedures, interassay variation of less
than 20% can be achieved [4,5]. Such assays are now
available for use in multicentre trials.
Putative therapeutic options
What can we do to prevent/overcome excessive
immunodepression? Following high-dose
immunosuppression in transplant patients using
corticosteroid bolus or pan-T-cell antibodies, we observed a
temporary decrease both in monocyte and T-cell function [6].
Long-lasting ‘immunoparalysis’ is predictive of the
occurrence and outcome of bacterial/fungal infectious
complications. Reduction in immunosuppression improved
immune function and antimicrobial defences. Those data
suggest a direct relation between immune responsiveness
and susceptibility to and course of infection.
However, what are the therapeutic options in patients who
are not immunosuppressed? As suggested above, a strong
perioperative systemic inflammation contributes to long-
lasting immune depression. Therefore, it makes sense to
attempt to prevent extensive counter-regulation by blocking
systemic inflammation. Angele and Faist [1] reported on a
pilot trial of granulocyte colony-stimulating factor (G-CSF) in
Figure 1
Regulation of monocytic HLA-DR, tumour necrosis factor (TNF)
secretion and antigen-presenting cell (APC) activity. G-CSF,
granulocyte colony-stimulating factor; GM-CSF, granulocyte/
macrophage colony-stimulating factor; IFN, interferon; LPS,
lipopolysaccharide; TGF, transforming growth factor.
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 surgical patients. Interestingly, G-CSF, which cannot directly
stimulate monocytes and T cells, prevented immune
deactivation (monocytic TNF secretion, HLA-DR expression,
IL-10 release, etc.). The mechanisms underlying this action
are not well understood. However, it is likely that, in addition
to the advanced antimicrobial capacity of G-CSF-activated
neutrophils, the anti-inflammatory capacity of G-CSF
contributes to the effect [7].
Endotoxin-neutralizing approaches may also help to prevent
inflammation-related immunodepression. In animal models,
targeting stress mediators (e.g. steroid receptor or β2-
adrenergic receptor antagonists) is very successful in
preventing immune depression [3], but transfer of this
approach from animal house to bedside is difficult because
of the short therapeutic window.
If ‘immunoparalysis’ becomes established, then
immunostimulatory approaches may be considered. In pilot
trials [8], treatment with plasmapheresis (removal of inhibitory
factors), interferon-γ and GM-CSF showed promise.
None of the approaches described above has yet been
tested in phase III trials. The availability of well standardized
immunoassays will now permit enrollment of patients with
‘immunoparalysis’ into multicentre trials.
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